CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL

July 30th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

CAR T-Cell Therapy MB-102 Granted FDA Orphan Drug Designation for AML

July 25th 2019

The CAR T-Cell therapy MB-102 has been granted an Orphan Drug Designation by the FDA, according to Mustang Bio, Inc, the manufacturer of the investigational treatment.

Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCL

July 19th 2019

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy

July 9th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas

July 3rd 2019

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

Expert Highlights CAR-T and Other Treatment Advances Across Hematologic Malignancies

July 2nd 2019

Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.

Dr. Shadman on Challenges With CAR T-Cell Therapy

June 28th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

June 28th 2019

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Dr. Galal on Managing AEs Linked With CAR T-Cell Therapy

June 25th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.

Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL

June 22nd 2019

Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

June 21st 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lisocabtagene Maraleucel Continues to Show Promise in Relapsed/Refractory CLL

June 21st 2019

The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Shadman on Next Steps for CAR T-Cell Therapy in DLBCL

June 11th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.

Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma

June 10th 2019

Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.

Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

June 4th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Shah on Differences Between Anti-CD19 CAR T-Cell Therapies

May 30th 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors

May 22nd 2019

Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.

Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas

May 15th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

FDA Grants P-BCMA-101 CAR T-Cell Therapy Orphan Drug Designation for Myeloma

May 14th 2019

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.